Michael E. Farkouh
- ASSOCIATE CLINICAL PROFESSOR Medicine, Cardiology
MD, University of Western Ontario
M.D., University of Western Ontario
University of Toronto
Mount Sinai Medical Center
Internship, Internal Medicine
University of Toronto
Residency, Internal Medicine
Fellowship, General Medicine
Mount Sinai Hospital
After obtaining his medical degree from the University of Western Ontario in 1988, Dr. Farkouh interned at the Toronto General Hospital. In 1992, he completed his residency at the Mayo Clinic followed by a fellowship in Academic General Internal Medicine from McMaster University where he studied for the Master of Science in Epidemiology under Professor David Sackett. Under the mentorship of Professor Salim Yusuf, Dr. Farkouh studied cardiovascular clinical trials. He completed his cardiovascular fellowship at Mount Sinai in 1998.
Dr. Farkouh has designed and conducted numerous pivotal clinical trials including: CHEER (Chest Pain Evaluation in the Emergency Room), TARGET, STATUS and FREEDOM (enrolling). His areas of research include: evaluation of chest pain syndromes, diabetes and heart diseases and the relationship of anti-inflammatory agents and heart disease. Dr. Farkouh is the PI for the BARI 2D and TRIUMPH trials at Mount Sinai. His past appointments include director of the telemetry unit at Mount Sinai, director of the cardiac care unit at New York University and director of the Electrocardiography Core Laboratory at the Cardiovascular Research Foundation. He has been awarded Teacher of the Year in the Department of Medicine at the Mayo Clinic. Dr. Farkouh has been an invited speaker internationally and served on numerous data safety monitoring boards.
The Clinical Trials Unit at Mount Sinai Heart serves as the clinical coordinating center for the NHLBI-sponsored FREEDOM trial and registry and for the REDEEM trial. The unit oversees clinical trial research throughout Mount Sinai Heart and interacts with various departments across the institution and beyond.
- Novel Imaging to Predict Cardiovascular Events in Diabetes
- Effects of High Dose Statin Therapy (FDG)/Atheroscleroti
- Multicenter, randomized, 12 week, double-blind, placebo-controlled, parallel-group, Phase IIA study using F-fluorodeoxyglucose (FDG)-PET to measure the effects of rilapladib on in-vivo macrophage activity in subjects with established atherosclerosis
- A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease
- Effect of VIA-2291 on Vascular Inflammation after ACS
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Farkouh during 2012 and/or 2013. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Scientific Advisory Board:
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.